ES2400293T3 - Derivados de indol e indolina ciclopropilamida como antagonistas de receptores EP4 - Google Patents

Derivados de indol e indolina ciclopropilamida como antagonistas de receptores EP4 Download PDF

Info

Publication number
ES2400293T3
ES2400293T3 ES08714673T ES08714673T ES2400293T3 ES 2400293 T3 ES2400293 T3 ES 2400293T3 ES 08714673 T ES08714673 T ES 08714673T ES 08714673 T ES08714673 T ES 08714673T ES 2400293 T3 ES2400293 T3 ES 2400293T3
Authority
ES
Spain
Prior art keywords
pharmaceutically acceptable
formula
compound according
compounds
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08714673T
Other languages
English (en)
Spanish (es)
Inventor
Michael Boyd
John Colucci
Yongxin Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Canada Inc
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Canada Inc, Merck Frosst Canada Ltd filed Critical Merck Canada Inc
Application granted granted Critical
Publication of ES2400293T3 publication Critical patent/ES2400293T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
ES08714673T 2007-02-26 2008-02-22 Derivados de indol e indolina ciclopropilamida como antagonistas de receptores EP4 Active ES2400293T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90349407P 2007-02-26 2007-02-26
US903494P 2007-02-26
PCT/CA2008/000351 WO2008104055A1 (en) 2007-02-26 2008-02-22 Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists

Publications (1)

Publication Number Publication Date
ES2400293T3 true ES2400293T3 (es) 2013-04-08

Family

ID=39720805

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08714673T Active ES2400293T3 (es) 2007-02-26 2008-02-22 Derivados de indol e indolina ciclopropilamida como antagonistas de receptores EP4

Country Status (8)

Country Link
US (1) US8158671B2 (enExample)
EP (1) EP2114877B1 (enExample)
JP (1) JP5301469B2 (enExample)
CN (1) CN101622230B (enExample)
AU (1) AU2008221194B2 (enExample)
CA (1) CA2679175C (enExample)
ES (1) ES2400293T3 (enExample)
WO (1) WO2008104055A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2141150B1 (en) 2007-04-26 2013-12-11 Takeda Pharmaceutical Company Limited Bicyclic compound and pharmaceutical use thereof
US8598355B2 (en) 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
US20110287112A1 (en) 2009-01-30 2011-11-24 Ono Pharmaceutical Co., Ltd. Prostate cancer progression inhibitor and progression inhibition method
WO2010121382A1 (en) * 2009-04-21 2010-10-28 Merck Frosst Canada Ltd. Process for making indole cyclopropyl amide derivatives
US8536179B2 (en) * 2010-05-07 2013-09-17 Glaxosmithkline Llc Indoles
EP3061751A1 (en) 2010-09-21 2016-08-31 Eisai R&D Management Co., Ltd. Pharmaceutical composition
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
ES2564353T3 (es) 2011-07-04 2016-03-22 Rottapharm Biotech S.R.L. Derivados de aminas cíclicas como agonistas de los receptores EP4
RU2565596C2 (ru) 2011-07-04 2015-10-20 Роттафарм Биотек С.Р.Л. Производные циклических аминов в качестве антагонистов рецептора ер4
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
WO2014143591A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
BR112015030315B1 (pt) * 2013-06-12 2022-10-04 Kaken Pharmaceutical Co., Ltd Derivado de 4-alquinilimidazol e produto farmacêutico que o compreende e antagonista de receptor de ep4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
CA3002144C (en) 2015-10-16 2024-01-23 Eisai R&D Management Co., Ltd. Ep4 antagonists
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
KR102473601B1 (ko) 2016-07-07 2022-12-01 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크 포인트 저해약을 포함하여 이루어진 조합
WO2018162562A1 (en) 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
US11066405B2 (en) * 2017-04-18 2021-07-20 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
US11738009B2 (en) 2017-04-18 2023-08-29 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
CN110612296A (zh) 2017-05-18 2019-12-24 爱杜西亚药品有限公司 作为pge2受体调节剂的苯基衍生物
MX394108B (es) 2017-05-18 2025-03-21 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos.
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
AU2018268311B2 (en) 2017-05-18 2022-02-10 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
TW201900180A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
WO2019038156A1 (en) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS
US12240860B2 (en) 2018-03-02 2025-03-04 Foshan Ionova Biotherapeutics Co., Inc. Heterobicyclic carboxylic acids and salts thereof
SG11202010153WA (en) 2018-04-17 2020-11-27 Tempest Therapeutics Inc Bicyclic carboxamides and methods of use thereof
KR20210040064A (ko) * 2018-07-12 2021-04-12 로타팜 바이오테크 에스.알.엘 Ep4 수용체 길항제로서의 (r)-4-(1-(1-(4-(트리플루오로메틸)벤질)피롤리딘-2-카복스아미드)사이클로프로필 벤조산
CN111989311B (zh) * 2019-01-22 2022-03-22 凯复(苏州)生物医药有限公司 抑制pge2/ep4信号传导的化合物、其制备方法及其在医药上的应用
EP3722319A1 (en) 2019-04-09 2020-10-14 Rottapharm Biotech S.r.l. Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours
EP3827828A1 (en) 2019-11-29 2021-06-02 Rottapharm Biotech S.r.l. (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossification
WO2021115560A1 (en) 2019-12-09 2021-06-17 Rottapharm Biotech S.R.L. New fyn and vegfr2 kinase inhibitors
EP3885339A1 (en) 2020-03-27 2021-09-29 Rottapharm Biotech S.r.l. Process for the preparation of (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료
WO2022247881A1 (zh) * 2021-05-28 2022-12-01 凯复(苏州)生物医药有限公司 治疗肿瘤的联合疗法
WO2022257960A1 (zh) * 2021-06-08 2022-12-15 武汉人福创新药物研发中心有限公司 用于治疗ep2、ep4受体介导的疾病的双环化合物
AU2022334637B2 (en) * 2021-08-27 2026-02-19 Keythera (Suzhou) Bio-Pharmaceuticals Co., Limited Solid form of indole compound, preparation method therefor and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743793B2 (en) * 2000-03-09 2004-06-01 Ono Pharmaceutical Co., Ltd. Indole derivatives, process for preparation of the same and use thereof
AU3445100A (en) * 2000-03-24 2001-10-08 Pharmagene Lab Ltd Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
JP2004513076A (ja) * 2000-07-25 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療で有用なｎ−置換インドール類
RS20060143A (sr) * 2003-09-03 2008-06-05 Pfizer Inc., Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2
US8013159B2 (en) * 2005-05-19 2011-09-06 Merck Canada Inc. Quinoline derivatives as EP4 antagonists
CA2648729A1 (en) * 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
US7705035B2 (en) * 2006-06-12 2010-04-27 Merck Frosst Canada Ltd. Indoline amide derivatives as EP4 receptor ligands

Also Published As

Publication number Publication date
EP2114877A4 (en) 2010-10-27
WO2008104055A1 (en) 2008-09-04
EP2114877A1 (en) 2009-11-11
AU2008221194B2 (en) 2013-06-27
US8158671B2 (en) 2012-04-17
CA2679175A1 (en) 2008-09-04
AU2008221194A1 (en) 2008-09-04
CN101622230B (zh) 2012-08-22
CA2679175C (en) 2015-01-13
US20090318518A1 (en) 2009-12-24
CN101622230A (zh) 2010-01-06
JP5301469B2 (ja) 2013-09-25
EP2114877B1 (en) 2012-12-26
JP2010519260A (ja) 2010-06-03

Similar Documents

Publication Publication Date Title
CA2679175C (en) Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
ES2392192T3 (es) Derivados de indol amida como antagonistas del receptor EP4
AU2007260529B2 (en) Indoline amide derivatives as EP4 receptor ligands
EP2346866B1 (en) Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
AU2008232265B2 (en) Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists
CA2608214C (en) Quinoline derivatives as ep4 antagonists